Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial

Neurology

Volumn 63, Issue 11, 2004, Pages 2104-2110

  Lesser, H ^a,d   Sharma, U ^b   LaMoreaux, L ^b   Poole, R M ^c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b PFIZER INC   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PREGABALIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; PAIN ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP; SOMNOLENCE; TREATMENT OUTCOME;

EID: 10444245040     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000145767.36287.A1     Document Type: Article

References (32)

1. Bryans JS, Wustrow DJ. 3-substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999;19:149-177.
2. Dworkin RH, Corbin AE, Young JP, Jr., et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60:1274-1283.
3. Sharma U, Glessner C, Corbin A. Pregabalin is efficacious for relief of painful diabetic neuropathy. Neurology 2002;58(7 suppl 3). Abstract.
4. 3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol 1993;244:303-309.
5. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280:107-110.
6. Maneuf YP, McKnight AT. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 2001;134:237-240.
7. 3H]-norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295:1086-1093.
8. Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001;132:1-4.
9. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229-236.
10. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003;105:133-141.
11. 3H]-norepinephrine release from rat neocortical slices. Synapse 2002;45:171-190.
12. Busch J, Strand JA, Posvar EL, et al. Pregabalin single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses. Epilepsia 1998;39(suppl 6):58. Abstract.
13. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998;280:1831-1836.
14. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-1842.
15. Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002;57:451-462.
16. Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double-blind, placebo controlled study. Pain 2001;94:215-224.
17. Jones DL, Sorkin LS. Systemic gabapentin and S(+)-3-isobutyl-gamma- aminobutyric acid block secondary hyperalgesia. Brain Res 1998;81:93-99.
18. Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. QJM 1998;91:733-737.
19. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-197.
20. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
21. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483.
22. McNair DM, Lorr M, Droppleman LF. POMS: Profile of Mood States. North Tonawanda, NY: Multi-Health Systems Inc., 1992.
23. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 4th ed. Rockville, MD: Dept. of Health and Human Services, FDA, 1996.
24. SAS/STAT User's Guide, version 6, 4th ed, volumes 1 and 2. Cary, NC: SAS, 1989.
25. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-802.
26. Farrar JT, Young JP, Jr., LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-158.
27. Guay DRP. Adjunctive agents in the management of chronic pain. Pharmacotherapy 2001;21:1070-1081.
28. Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther 2000;7:115-121.
29. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-596.
30. Rull JA, Quibrera R, Gonzalez-Millan H, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969;5:215-218.
31. Chadda VS, Mathur MS. Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Phys Ind 1978;26: 403-406.
32. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000;55:915-920.